COGT
USDCogent Biosciences Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$15.240
Kõrge
$15.870
Madal
$13.980
Maht
0.44M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
2.0B
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
1.89M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $21 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences with a Buy and maintains $21 price target.
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results
Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December Breakthrough Therapy Designation granted for bezuclastinib; New Drug Application (NDA)
Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting
SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential Novel JAK2 V617F mutant-selective inhibitor announced as Cogent's newest preclinical program;
Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
WALTHAM, Mass. and BOULDER, Colo., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today
JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $44
JP Morgan analyst Anupam Rama maintains Cogent Biosciences with a Overweight and raises the price target from $30 to $44.
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.